News
RCUS
15.62
-1.01%
-0.16
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Barchart · 3d ago
Arcus Biosciences price target lowered to $28 from $29 at BofA
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)
TipRanks · 5d ago
Weekly Report: what happened at RCUS last week (1109-1113)?
Weekly Report · 5d ago
Arcus Biosciences (RCUS) Could Be 57% Undervalued Following Third Quarter Results
Simply Wall St · 11/14 16:26
Arcus Biosciences Stock Faces Revenue Drop And Wider Nine Month Loss
Simply Wall St · 11/13 14:20
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11/12 21:05
Arcus Biosciences (RCUS) Stock Could Be Cheap Despite A 49% Five Year Fall
Simply Wall St · 11/12 13:23
Arcus Biosciences price target lowered to $40 from $41 at JPMorgan
TipRanks · 11/09 12:56
Weekly Report: what happened at RCUS last week (1102-1106)?
Weekly Report · 11/09 09:54
Arcus Biosciences (RCUS) Could Be 55% Undervalued As Third Quarter Losses Land
Simply Wall St · 11/07 14:22
Arcus Biosciences (RCUS) Gets a Hold from Morgan Stanley
TipRanks · 11/06 14:59
Arcus Biosciences Stock Misses Revenue as Kidney Cancer Trial Readout Nears
Simply Wall St · 11/06 13:30
Arcus Biosciences Is Maintained at Outperform by Leerink Partners
Dow Jones · 11/05 20:15
Arcus Biosciences Price Target Raised to $49.00/Share From $46.00 by Leerink Partners
Dow Jones · 11/05 20:15
Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49
Benzinga · 11/05 20:05
Arcus Biosciences Price Target Cut to $40.00/Share From $41.00 by Truist Securities
Dow Jones · 11/05 15:41
Arcus Biosciences Is Maintained at Buy by Truist Securities
Dow Jones · 11/05 15:41
Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40
Benzinga · 11/05 15:31
Arcus Biosciences Is Maintained at Outperform by Wedbush
Dow Jones · 11/05 13:56
More
Webull provides a variety of real-time RCUS stock news. You can receive the latest news about Arcus Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.